Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 8/20 | 0.57 |
| ▸ | CA12 | O43570 | 2/20 | 0.57 |
| ▸ | CA1 | P00915 | 2/20 | 0.57 |
| ▸ | CA2 | P00918 | 2/20 | 0.57 |
| ▸ | CA3 | P07451 | 2/20 | 0.57 |
| ▸ | CA4 | P22748 | 2/20 | 0.57 |
| ▸ | CA6 | P23280 | 2/20 | 0.57 |
| ▸ | CA5A | P35218 | 2/20 | 0.57 |
| ▸ | CA7 | P43166 | 2/20 | 0.57 |
| ▸ | CA9 | Q16790 | 2/20 | 0.57 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.57 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4203261 | 1.00 | DNM1 (0.57) | DNM1CA12CA1CA2CA3 | |
| SCHEMBL28158958 | 0.94 | DNM1 (0.50) | DNM1CA12CA1CA2CA3 | |
| SCHEMBL8589315 | 0.86 | DNM1 (0.68) | DNM1CA12CA1CA2CA3 | |
| SCHEMBL21318434 | 0.86 | DNM1 (0.68) | DNM1CA12CA1CA2CA3 | |
| SCHEMBL11180355 | 0.86 | DNM1 (0.60) | DNM1CA12CA1CA2CA3 | |
| SCHEMBL422834 | 0.85 | — | — | |
| Hydrochloric Acid SCHEMBL10953926 | 0.84 | TDP1 (0.50) | DNM1CA12CA1CA2CA3 | |
| Bromide SCHEMBL7747955 | 0.84 | DNM1 (0.70) | DNM1CA12CA1CA2CA3 | |
| SCHEMBL23471184 | 0.82 | — | — | |
| SCHEMBL8033562 | 0.82 | DNM1 (0.44) | DNM1CA12CA1CA2CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11242471-B2 | Conductive composition and conductive molded article | MITSUBOSHI BELTING LTD. (JP) | 2022-02-08 | — | — | US | disclosed |
| EP-3112425-A1 | CONDUCTIVE COMPOSITION AND CONDUCTIVE MOLDED ARTICLE | Mitsuboshi Belting Ltd. (JP) | 2017-01-04 | — | — | EP | disclosed |
| US-20160362585-A1 | Conductive Composition and Conductive Molded Article | MITSUBOSHI BELTING LTD. (JP) | 2016-12-15 | — | — | US | disclosed |
| EP-2559720-A1 | CROSSLINKED COMPOSITION | Daicel Corporation (JP) | 2013-02-20 | — | — | EP | disclosed |
| US-20130026458-A1 | CROSSLINKABLE COMPOSITION | DAICEL CORPORATION (JP) | 2013-01-31 | — | — | US | disclosed |
| CN-1266118-C | Novel delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides | NOVARTIS AG (CH) | 2006-07-26 | — | — | CN | disclosed |
| US-20060154926-A1 | Methods of treating alzheimer's disease using aryl alkanoic acid amides | ELAN PHARMACEUTICALS, INC. | 2006-07-13 | — | — | US | disclosed |
| CN-1550491-A | Novel delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides | ��˹��ŵ�� | 2004-12-01 | — | — | CN | disclosed |
| CN-1153759-C | Novel delta-amino-gamma hydroxy-omega-aryl-alkanamides | ��˹��ŵ�� | 2004-06-16 | — | — | CN | disclosed |
| WO-2003103653-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE USING ARYL ALKANOIC ACID AMIDES | ELAN PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | WO | disclosed |
| US-5705658-A | HYPOTENSIVE AGENTS | NOVARTIS CORPORATION (US) | 1998-01-06 | — | — | US | disclosed |
| US-5654445-A | INTERMEDIATES FOR RENIN INHIBITORS, HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1997-08-05 | — | — | US | disclosed |
| US-5646143-A | FOR TREATING A VARIETY OF CONDITIONS | CIBA-GEIGY CORPORATION (US) | 1997-07-08 | — | — | US | disclosed |
| US-5627182-A | RENIN INHIBITORS FOR USE AS HYPOTENSIVE AGENTS | CIBA GEIGY CORPORATION (US) | 1997-05-06 | — | — | US | disclosed |
| US-5559111-A | HYPOTENSIVE AGENTS; RENIN INHIBITORS; Aliskiren | CIBA-GEIGY CORPORATION (US) | 1996-09-24 | — | — | US | disclosed |
| CN-1117960-A | Novel delta-amino-gamma hydroxy-omega-aryl-alkanamides | CIBA GEIGY AG (CH) | 1996-03-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130026458-A1 | CROSSLINKABLE COMPOSITION | DDC, ODC1, SRM | DNM1 3876/4885CA12 3427/4885CA1 1891/4885 |
| US-20060154926-A1 | Methods of treating alzheimer's disease using aryl alkanoic acid amides | BACE1, APP, PSEN1 | DNM1 1347/4885CA12 2443/4885CA1 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.